专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006108591A1 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS 审中-公开
标题翻译： 1H-QUINAZ0LINE-2,4-DIONES及其作为AMPA受体配体的用途
公开(公告)号：WO2006108591A1
公开(公告)日：2006-10-19
申请号：PCT/EP2006/003251
申请日：2006-04-10
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , ALLGEIER, Hans , AUBERSON, Yves , CARCACHE, David , FLOERSHEIM, Philipp , GUIBOURDENCHE, Christel , FROESTL, Wolfgang , KALLEN, Jörg , KOLLER, Manuel , MATTES, Henri , NOZULAK, Joachim , ORAIN, David , RENAUD, Johanne
发明人： ALLGEIER, Hans , AUBERSON, Yves , CARCACHE, David , FLOERSHEIM, Philipp , GUIBOURDENCHE, Christel , FROESTL, Wolfgang , KALLEN, Jörg , KOLLER, Manuel , MATTES, Henri , NOZULAK, Joachim , ORAIN, David , RENAUD, Johanne
IPC分类号： C07D239/96 , A61K31/517 , A61P25/08 , A61P25/18 , C07D405/04 , C07D403/04 , C07D401/04 , C07D413/04 , C07D307/16 , C07D309/12 , C07D231/12 , C07D249/06 , C07D207/32 , C07D307/54 , C07D237/08
CPC分类号： C07D239/96 , C07C207/00 , C07C229/56 , C07C229/64 , C07C229/66 , C07C255/18 , C07C265/12 , C07C271/58 , C07D207/337 , C07D231/12 , C07D237/08 , C07D239/26 , C07D241/12 , C07D249/06 , C07D263/32 , C07D307/16 , C07D307/54 , C07D309/12 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/04
摘要： The present invention relates to l H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schizophrenia, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) and combinations comprising compounds of formula (I) are disclosed.
摘要翻译：本发明涉及式（I）的1H-喹唑啉-2,4-二酮，其中R 1和R 2如说明书中所定义，它们的制备，它们用作AMPA受体配体，特别是用于治疗癫痫或精神分裂症，以及含有它们的药物组合物。此外，公开了用于制备式（I）化合物的中间体和包含式（I）化合物的组合。

2. 发明申请

WO2009047359A1 INHIBITORS OF PROTEIN KINASES 审中-公开
标题翻译：蛋白激酶抑制剂
公开(公告)号：WO2009047359A1
公开(公告)日：2009-04-16
申请号：PCT/EP2008/063715
申请日：2008-10-13
申请人： INGENIUM PHARMACEUTICALS GMBH , ALLGEIER, HANS , AUGUSTIN, MARTIN , MUELLER, ANKE , ZEITLMANN, LUTZ , MARQUARDT, ANDREAS , PLEISS, MICHAEL A. , HEISER, ULRICH , NIESTROJ, ANDRÉ JOHANNES
发明人： ALLGEIER, HANS , AUGUSTIN, MARTIN , MUELLER, ANKE , ZEITLMANN, LUTZ , MARQUARDT, ANDREAS , PLEISS, MICHAEL A. , HEISER, ULRICH , NIESTROJ, ANDRÉ JOHANNES
IPC分类号： C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D471/04 , C07D487/04 , A61K31/505 , A61P25/28 , A61P29/00 , A61P9/00 , A61P25/00
CPC分类号： C07D403/12 , C07D239/42 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D471/04 , C07D487/04
摘要： Compounds of general Formula I, wherein R 1 , R 2 , R 3 , x, A and R a are as defined herein are inhibitors of cyclin-dependent kinases and are useful for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
摘要翻译：通式I的化合物，其中R 1，R 2，R 3，X，A和R a如本文所定义，是细胞周期蛋白依赖性激酶的抑制剂，并且可用于预防和/或治疗任何类型的疼痛，炎症性疾病，免疫性疾病，增殖性疾病，传染病，心血管疾病和神经退行性疾病。

3. 发明申请

WO2008129070A1 INHIBITORS OF PROTEIN KINASES 审中-公开
标题翻译：蛋白激酶抑制剂
公开(公告)号：WO2008129070A1
公开(公告)日：2008-10-30
申请号：PCT/EP2008/054975
申请日：2008-04-24
申请人： INGENIUM PHARMACEUTICALS GMBH , WABNITZ, Philipp , SCHAUERTE, Heike , ALLGEIER, Hans , AUGUSTIN, Martin , ZEITLMANN, Lutz , PLEISS, Michael A. , STUMM, Gabriele , MUELLER, Anke
发明人： WABNITZ, Philipp , SCHAUERTE, Heike , ALLGEIER, Hans , AUGUSTIN, Martin , ZEITLMANN, Lutz , PLEISS, Michael A. , STUMM, Gabriele , MUELLER, Anke
IPC分类号： C07D239/42 , A61K31/505 , A61P29/00
CPC分类号： C07D239/42
摘要： The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
摘要翻译：本发明涉及细胞周期蛋白依赖性激酶的抑制剂及其治疗应用。此外，本发明涉及预防和/或治疗任何类型的疼痛，炎性疾病，免疫疾病，增殖性疾病，感染性疾病，心血管疾病和神经变性疾病的方法，包括施用有效量的至少一种细胞周期蛋白抑制剂，依赖性激酶。

4. 发明申请

WO1998017672A1 SUBSTITUTED AMINOALKANE PHOSPHONIC ACIDS 审中-公开
标题翻译：取代aminoalkanephosphonic酸
公开(公告)号：WO1998017672A1
公开(公告)日：1998-04-30
申请号：PCT/EP1997005843
申请日：1997-10-22
申请人： NOVARTIS AG , ACKLIN, Pierre , ALLGEIER, Hans , AUBERSON, Yves , OFNER, Silvio , VEENSTRA, Siem, Jacob
发明人： NOVARTIS AG
IPC分类号： C07F09/6509
CPC分类号： C07F9/650994
摘要： Compounds have the formula (I), in which R1 stands for hydroxy or an aliphatic, araliphatic or aromatic radical; X stands for a bivalent aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical; R2 stands for hydrogen or an aliphatic or araliphatic radical; alk stands for lower alkylidene; and R3, R4 and R5 independently represent hydrogen, lower alkyl, halogen, trifluoromethyl, cyano or nitro. These compounds and their salts may be used for treating pathological conditions which respond to the blocking of exciter amino acid receptors, and for producing pharmaceutical compositions.
摘要翻译：式（I）其中R1是羟基或脂族，芳脂族或芳族基团的化合物; X为二价脂族，脂环族，脂环族 - 脂族，芳脂族，heteroarylaliphatic或芳族基团; R 2表示氢或脂族或芳脂族基团，alk是低级亚烷基; 和R 3，R 4和R 5独立地是氢，低级烷基，卤素，三氟甲基，氰基或硝基; 和它们的盐可被用于其中兴奋性氨基酸受体的阻断响应的病理状况的治疗，以及用于生产药物制剂。

5. 发明申请

WO1997008155A1 NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES 审中-公开
标题翻译：新的2,3-二氧代-1,2,3,4-四氢喹啉衍生物
公开(公告)号：WO1997008155A1
公开(公告)日：1997-03-06
申请号：PCT/EP1996003644
申请日：1996-08-19
申请人： NOVARTIS AG , ACKLIN, Pierre , ALLGEIER, Hans , AUBERSON, Yves , BIOLLAZ, Michel , MORETTI, Robert , OFNER, Silvio , VEENSTRA, Siem, Jacob
发明人： NOVARTIS AG
IPC分类号： C07D241/44
CPC分类号： C07D401/06 , C07D241/44 , C07D401/12 , C07D417/12 , C07F9/650994
摘要： 2,3-Dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives of formula (I), wherein one of the radicals R1, and R2 is a group R5 and the other is a group of formula -CH(R6)-alk-R7 (Ia), -alk-CH(R6-R7 (Ib), -alk-N(R8)-X-R7 (Ic), -alk-N (R8)(R9)-X-R7A (Id), -alk-O-X-R7 (Ie) or -alk-S-X-R7 (If), R3, R4 and R5 are each independently of the others hydrogen, lower alkyl, halogen, trifluoromethyl, cyano or nitro, R6 is unsubstituted or lower alkylated and/or lower alkanoylated amino, R7 is hydrogen; an aliphatic, cycloaliphatic or heterocycloaliphatic radical; cyano; acyl derived from carbonic acid or from a semiester or semiamide of carbonic acid, from sulfuric acid or from an aliphatic or aromatic sulfonic acid or from phosphoric acid or from a phosphonic acid ester; amino that is unsubtituted or aliphatically or araliphatically substituted and/or substituted by aliphatic, araliphatic or aromatic acyl; or an aromatic or heteroaromatic radical, R8 is hydrogen; an aliphatic or araliphatic radical; or acyl derived from an aliphatic or araliphatic carboxylic acid or from an aliphatic or araliphatic semiester of carbonic acid, or R7 and R8, together with X and the nitrogen atom bonding R8 and X, form an unsubstitued or substituted mono- or di-azaxycloalkyl, azoxacycloalkyl, azathiacycloalkyl or optionally oxidised thiacycloalkyl radical bonded via a nitrogen atom, or an unsubstituted or substituted, optionally partially hxdrogenated aryl or heteroaryl radical, R9 is an aliphatic or araliphatic radical, or R7, R8 and R9 together with X and the nitrogen atom bonding R8, R9 and X, form an unsubstituted or substituted quaternary heteroaryl radical bonded via the quaternary nitrogen atom, with A being the anion of a protonic acid, alk is lower alkylene, and X (unless, together with R7 and R8 and the nitrogen atom bonding R8 and X or together with the nitrogen atom bonding R8, R9 and X, it forms part of one of the mentioned ring systems) is a divalent aliphatic, cycloaliphatic or araliphatic radical or a direct bond, and the pharmaceutically acceptable salts thereof can be used in the preparation of a medicament for the treatment of pathological conditions that are responsive to blocking of AMPA, kainate and/or glycine binding sites of the NMDA receptor.
摘要翻译：式（I）的2,3-二氧代-1,2,3,4-四氢 - 喹喔啉基衍生物，其中基团R 1和R 2之一是基团R 5，另一个是式-CH（R 6） -alk-R7（Ia），-alk-CH（R6-R7（Ib））-alk-N（R8）-X-R7（Ic），-alk-N +（R8）（R9）-X -R7A - （Id），-alk-OX-R7（Ie）或-alk-SX-R7（If），R3，R4和R5各自独立地为氢，低级烷基，卤素，三氟甲基，氰基或硝基，R 6是未取代的或低级烷基化的和/或低级烷酰基化的氨基，R 7是氢;脂族，脂环族或杂环脂族基团;氰基;衍生自碳酸的酰基或来自碳酸的半酯或半酰胺，脂族或芳族磺酸或磷酸或膦酸酯;未取代或脂族或芳烃取代和/或被脂族或芳族酰基取代的氨基;或芳族或杂芳族基团，R 8为氢; 脂肪族或芳脂族辐射 CAL; 或衍生自脂族或芳脂族羧酸的酰基或来自碳酸或R 7和R 8的脂族或芳脂肪族半酯与X以及键合R 8和X的氮原子形成未取代或取代的单 - 或二 - 氮杂环烷基的酰基，氮杂环烷基，氮杂环烷基或任意氧化的经氮原子键合的硫代环烷基，或未取代或取代的，任选部分羟基化的芳基或杂芳基，R 9为脂族或芳脂族基，或者R 7，R 8和R 9与X和氮原子键合 R8，R9和X形成通过季氮原子键合的未取代或取代的季杂芳基，A 1是质子酸的阴离子，alk是低级亚烷基和X（除非与R 7和R 8一起键合R8和X的氮原子或与R8，R9和X键合的氮原子一起形成所述环系中一个的一部分）是二价脂族，脂环族或芳族脂肪族基团或直接键合，并且其药学上可接受的盐可用于制备用于治疗对阻断NMDA受体的AMPA，红藻氨酸和/或甘氨酸结合位点有反应的病理状况的药物。

6. 发明申请

WO2008065155A1 CDK INHIBITORS FOR TREATING PAIN 审中-公开
标题翻译：用于治疗疼痛的CDK抑制剂
公开(公告)号：WO2008065155A1
公开(公告)日：2008-06-05
申请号：PCT/EP2007/062979
申请日：2007-11-29
申请人： INGENIUM PHARMACEUTICALS AG , AUGUSTIN, Martin , STUMM, Gabriele , ALLGEIER, Hans , MARQUARDT, Andreas , ZEITLMANN, Lutz
发明人： AUGUSTIN, Martin , STUMM, Gabriele , ALLGEIER, Hans , MARQUARDT, Andreas , ZEITLMANN, Lutz
IPC分类号： A61P25/04 , A61P29/00 , A61K31/505 , A61K31/506
CPC分类号： A61K31/505 , A61K31/506
摘要： The present invention relates to methods of preventing and/or treating any type of pain comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
摘要翻译：本发明涉及预防和/或治疗任何类型的疼痛的方法，包括施用有效量的至少一种细胞周期蛋白依赖性激酶抑制剂。

7. 发明申请

WO2008049856A2 METHODS OF TREATING PAIN 审中-公开
标题翻译：治疗疼痛的方法
公开(公告)号：WO2008049856A2
公开(公告)日：2008-05-02
申请号：PCT/EP2007/061415
申请日：2007-10-24
申请人： INGENIUM PHARMACEUTICALS AG , AUGUSTIN, Martin , ZEITLMANN, Lutz , STUMM, Gabriele , PLEISS, Michael A. , WABNITZ, Philipp , ALLGEIER, Hans
发明人： AUGUSTIN, Martin , ZEITLMANN, Lutz , STUMM, Gabriele , PLEISS, Michael A. , WABNITZ, Philipp , ALLGEIER, Hans
IPC分类号： A61K31/427 , A61K31/4439 , A61K31/454 , A61P29/00
CPC分类号： A61K31/427 , A61K31/4439 , A61K31/454
摘要： The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
摘要翻译：本发明涉及细胞周期蛋白依赖性激酶的抑制剂及其治疗应用。此外，本发明涉及预防和/或治疗任何类型的疼痛的方法，其包括施用有效量的至少一种细胞周期蛋白依赖性激酶抑制剂。

8. 发明申请

WO2011048150A1 USE OF 1H-QUINAZOLINE-2,4-DIONES 审中-公开
标题翻译：使用1H-喹唑啉-2,4-二酮
公开(公告)号：WO2011048150A1
公开(公告)日：2011-04-28
申请号：PCT/EP2010/065805
申请日：2010-10-20
申请人： NOVARTIS AG , ALLGEIER, Hans , AUBERSON, Yves , AVRAMEAS, Alexandre , BLAETTLER, Thomas , CARCACHE, David , FLOERSHEIM, Philipp , FROESTL, Wolfgang , GUIBOURDENCHE, Christel , KALKMAN, Hans, O. , KALLEN, Joerg , KOLLER, Manuel , LINGENHÖHL, Kurt , MA, Shenglin , MATTES, Henri , NOZULAK, Joachim , ORAIN, David , RENAUD, Johanne , STROHMAIER, Christine
发明人： ALLGEIER, Hans , AUBERSON, Yves , AVRAMEAS, Alexandre , BLAETTLER, Thomas , CARCACHE, David , FLOERSHEIM, Philipp , FROESTL, Wolfgang , GUIBOURDENCHE, Christel , KALKMAN, Hans, O. , KALLEN, Joerg , KOLLER, Manuel , LINGENHÖHL, Kurt , MA, Shenglin , MATTES, Henri , NOZULAK, Joachim , ORAIN, David , RENAUD, Johanne , STROHMAIER, Christine
IPC分类号： A61K31/517 , A61P25/08
CPC分类号： A61K31/517 , A61K31/34
摘要： The invention concerns the use of competitive AMPA receptor antagonists for the treatment, prevention or delay of progression of Rasmussen's encephalitis and/or certain forms of epilepsy.
摘要翻译：本发明涉及竞争性AMPA受体拮抗剂用于治疗，预防或延缓拉斯穆森脑炎和/或某些形式的癫痫发展的用途。

9. 发明申请

WO2008153967A1 BK1 ANTAGONIST CONJUGATES 审中-公开
标题翻译： BK1拮抗剂
公开(公告)号：WO2008153967A1
公开(公告)日：2008-12-18
申请号：PCT/US2008/007157
申请日：2008-06-06
申请人： CONTEC THERAPEUTICS, INC. , PLEISS, Michael, A. , FREEDMAN, Stephen, B. , ALLGEIER, Hans , PERAUS, Gisela , STUMM, Gabriele , DEMBOWSKY, Klaus , NEHLS, Michael, C. , AUGUSTIN, Martin
发明人： PLEISS, Michael, A. , FREEDMAN, Stephen, B. , ALLGEIER, Hans , PERAUS, Gisela , STUMM, Gabriele , DEMBOWSKY, Klaus , NEHLS, Michael, C. , AUGUSTIN, Martin
IPC分类号： C07K16/00 , C12P21/08
CPC分类号： A61K47/55 , A61K9/0048 , A61K47/60
摘要： The present invention relates to conjugated BK1 antagonists. The conjugated BK1 antagonists comprise a small molecule or peptide, covalently bound to a linker molecule, said linker molecule being covalently bound to a biocompatible polymer, such as PEG. Linker molecule and biocompatible conjugated BK1 antagonists of the invention are useful in the treatment of various diseases, including autoimmune diseases and pain.
摘要翻译：本发明涉及缀合的BK1拮抗剂。缀合的BK1拮抗剂包含与连接分子共价结合的小分子或肽，所述连接体分子与生物相容性聚合物如PEG共价结合。本发明的接头分子和生物相容性缀合的BK1拮抗剂可用于治疗各种疾病，包括自身免疫疾病和疼痛。

10. 发明申请

WO2008129080A1 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES 审中-公开
标题翻译：作为蛋白激酶抑制剂的4,6-取代的氨基嘧啶衍生物
公开(公告)号：WO2008129080A1
公开(公告)日：2008-10-30
申请号：PCT/EP2008/055017
申请日：2008-04-24
申请人： INGENIUM PHARMACEUTICALS GMBH , WABNITZ, Philipp , SCHAUERTE, Heike , ALLGEIER, Hans , AUGUSTIN, Martin , ZEITLMANN, Lutz , PLEISS, Michael A. , STUMM, Gabriele , MUELLER, Anke , CHOIDAS, Axel , KLEBL, Bert , MUELLER, Gerhard , SCHWAB, Wilfried , LE, Jolle , MACRITCHIE, Jackie , SIMPSON, Don
发明人： WABNITZ, Philipp , SCHAUERTE, Heike , ALLGEIER, Hans , AUGUSTIN, Martin , ZEITLMANN, Lutz , PLEISS, Michael A. , STUMM, Gabriele , MUELLER, Anke , CHOIDAS, Axel , KLEBL, Bert , MUELLER, Gerhard , SCHWAB, Wilfried , LE, Jolle , MACRITCHIE, Jackie , SIMPSON, Don
IPC分类号： C07D239/42 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , A61K31/505 , A61P35/00
CPC分类号： C07D239/42 , C07D239/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12
摘要： The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
摘要翻译：本发明涉及细胞周期蛋白依赖性激酶的通式（I）的抑制剂及其治疗应用。此外，本发明涉及用于预防和/或治疗任何类型的疼痛，炎症性疾病，免疫疾病，增殖性疾病，感染性疾病，心血管疾病和神经变性疾病的化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式